Applied Therapeutics, Inc. Common Stock (APLT)
Applied Therapeutics, Inc. is a biotechnology company focused on developing treatments for serious, rare, and unmet medical conditions, particularly in the areas of metabolic and neurodegenerative diseases. The company utilizes a novel approach to drug discovery, leveraging its proprietary platform to identify and develop targeted therapies aimed at addressing underlying disease mechanisms.
Company News
Law firm Grabar Law Office is investigating potential securities fraud and fiduciary duty breaches for several publicly traded companies, alleging misleading statements and concealed material facts that impacted investor decisions.
Applied Therapeutics (APLT) has been upgraded to a Zacks Rank #2 (Buy), reflecting an upward trend in earnings estimates. This positive outlook is expected to have a favorable impact on the stock price.
The FDA has canceled the Advisory Committee meeting to review Applied Therapeutics' New Drug Application for govorestat, a drug to treat galactosemia. This increases the likelihood of FDA approval, leading to a 70.5% surge in Applied Therapeutics' stock price.
G1 Therapeutics (GTHX) delivered earnings and revenue surprises of -5.26% and 4.84%, respectively, for the quarter ended March 2024. Do the numbers hold clues to what lies ahead for the stock?
3 top penny stocks to watch with insider buying this month. The post 3 Penny Stocks To Buy According To Insiders In December appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.